USDC Moved $36 Trillion, but Circle's Economics Still Favor Partners

CoreWeave's equity sell-off is being reinforced by a harsher signal from the credit market. Five-year credit-default swaps on the AI infrastructure provider moved above 1,000 basis points, while a bond due in 2031 yielded about 14.5% on October 16 after nearly reaching 16%.

A credit-default swap is insurance against a borrower's failure to repay. At a quote of 1,000 basis points, insuring $1 million of debt costs more than $100,000 a year before contract details. CNBC, citing Bloomberg pricing, said the market implied roughly a 60% probability of default within five years. That is a model-based market estimate, not a prediction that default will occur.

The bond comparison shows how sharply financing conditions changed. The 2031 security was issued in April at a 9.75% yield. A jump to 14.5% means investors demand substantially more compensation to hold the same debt, which can make future borrowing or refinancing more expensive. CoreWeave shares fell about 25% over the week as the credit move accelerated.

The counterevidence is substantial demand. CoreWeave reported record second-quarter revenue and backlog, and later said it added more than $25 billion of net new customer commitments early in the third quarter. Nvidia Chief Executive Jensen Huang also said the company's financial position was stable and improving. Customer commitments support future revenue, but they do not eliminate the timing mismatch between heavy upfront construction costs and cash collected over long contracts.

For equity investors, the central issue is not whether a default happens tomorrow. It is whether CoreWeave can fund capacity, service debt and preserve value for shareholders while its cost of capital is elevated. The next earnings report should be judged on cash flow, debt maturities, collateral requirements and customer concentration, not backlog alone.

Reddit's premium valuation rests on a simple claim: growth is fast enough to justify paying more for each dollar of earnings than investors pay for larger advertising platforms. The company's second-quarter results support part of that case, while its third-quarter outlook shows why the premium is not risk-free.

Revenue reached $804.9 million in the second quarter, up 61% from a year earlier. Weekly active uniques rose 24% to 514.6 million, crossing half a billion, and ad revenue reached $762 million. The original comparison also notes that active advertisers grew more than 70% and revenue from Reddit's scaled channel doubled.

Management guided to third-quarter revenue of $860 million to $870 million. Against the prior-year base, that represents roughly 47% to 49% growth, a meaningful slowdown from 61%. Deceleration from a high rate is not the same as contraction, but it matters when the stock's valuation assumes Reddit will keep outgrowing Meta, Alphabet and other advertising peers.

Profitability is the second test. The source comparison calculated a 28.2% operating margin over the four quarters through June 2026, below Meta's 38.1% but far above Reddit's own 7.9% in the comparable year-earlier period. Those calculations use matched four-quarter windows, which makes them more useful than comparing isolated quarterly margins.

Traffic from search remains a separate risk because Reddit has limited control over referral algorithms. Management described search traffic as volatile and said visibility was low. The next report must show whether direct usage and advertiser growth can offset that variability while margins continue to expand. Reddit has earned a growth premium; the debate is how much of that progress is already reflected in the price.

Disc Medicine reported a clean Phase 3 result for bitopertin, sending the clinical-stage biotech's shares sharply higher. In the 183-patient APOLLO trial, the drug met both primary endpoints for erythropoietic protoporphyria, a rare disorder that causes severe pain after light exposure.

The trial measured both biology and daily function. Whole-blood metal-free protoporphyrin IX fell 41.4% versus placebo, with a p-value below 0.0001. During the sixth month of treatment, patients gained an average 12.2 hours per month in light without pain versus placebo, with a p-value of 0.0010. Disc also said every secondary endpoint reached statistical significance.

Safety remains part of the decision. Dizziness was the most common treatment-emergent adverse event, affecting 50% of patients on bitopertin, although the company described the cases as mild or moderate and generally temporary. The trial enrolled adults and adolescents age 12 and older with EPP or X-linked protoporphyria.

The regulatory history explains why the stock reaction was so large. The Food and Drug Administration previously issued a Complete Response Letter after concluding that earlier studies did not establish an association between the PPIX biomarker and sunlight-exposure endpoints. Disc later said a Type A meeting aligned the company and agency on APOLLO as a potential basis for its response if the trial succeeded. Success therefore addresses the central evidentiary gap, but it does not guarantee approval.

Disc plans to submit its response in late 2026 and expects an FDA decision by mid-2027. Bitopertin remains investigational and is not approved in any jurisdiction. With approximately $718 million in cash, equivalents and marketable securities at June 30, the company says it has runway into 2029. The next decisive evidence is whether the FDA accepts the package and how it evaluates the drug's safety-benefit profile.

Income investors comparing AT&T with Comcast face a trade-off between yield and structural simplicity. Comcast’s annual dividend of $1.32 implies a yield near 6.5% at the price cited in the source, above AT&T’s roughly 4.6% yield on a $1.11 annual dividend.

Cash coverage also favors Comcast on trailing figures. The source calculated that dividends consumed about 24% of Comcast’s free cash flow over the 12 months through June 30, compared with about 45% for AT&T. Consensus figures cited for 2026 put the ratios near 36% and 46%, respectively. These are useful comparisons, but free cash flow can move with capital spending and working capital, so a single year should not be treated as permanent capacity.

AT&T’s advantage is focus. Its plan centers on wireless and fiber, and management has targeted at least $18 billion of free cash flow for 2026. The company still carries substantial debt, but the dividend framework is easier to evaluate because the operating perimeter is relatively clear.

Comcast is preparing to separate a group of cable networks and digital assets from the remaining broadband, wireless, studios and theme-park businesses. The transaction can sharpen strategic focus, yet it creates an unresolved question for dividend investors: how the current payment, debt and cash flow will be divided between the two companies. Until boards set post-separation policies, the headline yield does not guarantee the same income stream after the transaction.

Comcast currently offers the richer yield and stronger recent cash coverage. AT&T offers a more straightforward path for investors who prioritize predictability. The better choice depends on whether Comcast’s separation preserves dividend capacity and whether AT&T delivers its cash-flow targets while reducing leverage. Neither stock’s dividend should be projected for a decade without accounting for business change, capital needs and board decisions.

Both companies therefore require cash-flow monitoring, not yield comparison alone.